Startup profile · funding coverage
Multiply Labs funding, valuation and investors
Robotic manufacturing systems for cell therapies, gene therapies, mRNA medicines and other complex biologics.
Keep track of Multiply Labs
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$75M · October 6, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$75M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · San Francisco, California
Investors in latest funding
Lead: NantWorks
Other: AstraZeneca Ventures , Lingotto Innovation , Legend Biotech , Fifty Years , Ora Global , Teradyne Ventures , Strange Ventures , Casdin Capital , Lux Capital , Founders Fund
Overview
Multiply Labs is a San Francisco robotics company founded in 2016. It develops modular robotic systems that automate manufacturing steps for complex medicines, including cell and gene therapies and mRNA products. Drugmakers deploy the machines inside their own facilities; Multiply also sells consumable cartridges plus service and support. The company announced a $75 million Series B in October 2026, taking total capital raised above $100 million.
Why Multiply Labs is interesting
Multiply addresses the manufacturing bottleneck that sits between AI-assisted drug discovery and patient delivery. Its commercial test is whether a small number of multimillion-dollar machines can become a repeatable platform with attractive hardware, consumables and service economics.
Product & use cases
Modular robotic biomanufacturing systems that automate laboratory and production workflows for advanced medicines. The business combines hardware sales with recurring cartridges, maintenance and support.
- Automating cell- and gene-therapy manufacturing workflows
- Producing mRNA medicines with reduced manual handling
- Standardizing complex pharmaceutical manufacturing across sites
Key facts
- October 2026: announced a $75M Series B led by NantWorks, bringing disclosed capital above $100M.
- Customers and strategic investors include AstraZeneca and Legend Biotech.
- Company says its installed base remains in the high single digits, highlighting both commercial validation and early scale.
Funding history (newest first)
Series B
2026-10-06 $75M- NantWorks (lead)
- AstraZeneca Ventures (participant)
- Lingotto Innovation (participant)
- Legend Biotech (participant)
- Fifty Years (participant)
- Ora Global (participant)
- Teradyne Ventures (participant)
- Strange Ventures (participant)
- Casdin Capital (participant)
- Lux Capital (participant)
- Founders Fund (participant)
Investors in our directory
Funds linked from Multiply Labs's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: The platform is designed around complex drug-manufacturing workflows rather than general industrial automation, and has strategic validation from drugmakers including AstraZeneca and Legend Biotech.
Multiply competes with established bioprocess-equipment suppliers, custom automation integrators and internal drugmaker engineering teams. Its advantage is purpose-built modular robotics; its risk is high hardware cost, a long validation cycle and a small installed base.
-
Thermo Fisher Scientific incumbent
Large bioprocessing and laboratory-equipment supplier with global distribution and service.
-
Cytiva incumbent
Provides bioprocessing systems and consumables to biopharma manufacturers.
-
HighRes Biosolutions direct
Develops laboratory automation systems used across life-science workflows.
-
Custom systems integrators alternative
Drugmakers can commission bespoke automation from established engineering firms.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Multiply Labs's financing or category context.
FAQs about Multiply Labs
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.